List view / Grid view

Boehringer Ingelheim

 

news

Two-year study in over 1,500 patients compares Trajenta® (linagliptin) to the commonly prescribed sulphonylurea glimepiride

28 June 2012 | By Boehringer Ingelheim

Results from a two-year study published in The Lancet today demonstrate that Trajenta® (linagliptin) provides similar blood glucose improvements when compared to the commonly prescribed sulphonylurea, glimepiride, in adult patients with type 2 diabetes (T2D) inadequately controlled on metformin alone. The publication also describes that linagliptin was associated with significantly…